EBR:SEQUA - Euronext Brussels - BE0974340722 - Common Stock - Currency: EUR
EBR:SEQUA (3/6/2025, 7:00:00 PM)
1.49
+0.05 (+3.47%)
The current stock price of SEQUA.BR is 1.49 EUR. In the past month the price decreased by -32.09%. In the past year, price decreased by -33.64%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABL.DE | ABBOTT LABORATORIES | 28.76 | 217.99B | ||
1ISRG.MI | INTUITIVE SURGICAL INC | 78.6 | 192.03B | ||
IUI1.DE | INTUITIVE SURGICAL INC | 75.09 | 183.47B | ||
BSX.DE | BOSTON SCIENTIFIC CORP | 40.64 | 140.75B | ||
2M6.DE | MEDTRONIC PLC | 17.32 | 110.84B | ||
BOX.DE | BECTON DICKINSON AND CO | 16.03 | 59.90B | ||
SHL.DE | SIEMENS HEALTHINEERS AG | 23.63 | 59.45B | ||
EWL.DE | EDWARDS LIFESCIENCES CORP | 27.48 | 39.71B | ||
DC4.DE | DEXCOM INC | 48.87 | 29.40B | ||
PHI1.DE | KONINKLIJKE PHILIPS NV | 18.17 | 23.74B | ||
PHIA.AS | KONINKLIJKE PHILIPS NV | 18.17 | 23.73B | ||
1PHIA.MI | KONINKLIJKE PHILIPS NV | 18.06 | 23.59B |
Sequana Medical NV is a commercial stage medical device company, which engages in the design, development, manufacture, and commercialization of medical device. The company is headquartered in Ghent, Oost-Vlaanderen and currently employs 62 full-time employees. The company went IPO on 2019-02-11. The firm focuses mainly on the development of treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders. Sequana Medical NV provides alfapump, which is an implantable, programmable, wireless-charged and battery-powered system that is CE-marking for the management of refractory ascites due to liver cirrhosis and malignant ascites. Over 650 alfapump systems have been implanted. Apart from the Alfapump, the Company also aims to develop a direct sodium removal (DSR) therapy, which is a propriety approach to the treatment of volume overload in heart failure.
SEQUANA MEDICAL NV
Kortrijksesteenweg 1112, Sint-Denijs-Westrem
Ghent OOST-VLAANDEREN BE
Employees: 62
Company Website: https://www.sequanamedical.com/
Investor Relations: http://www.sequanamedical.com/investors/
Phone: 3292928065.0
The current stock price of SEQUA.BR is 1.49 EUR. The price increased by 3.47% in the last trading session.
The exchange symbol of SEQUANA MEDICAL NV is SEQUA and it is listed on the Euronext Brussels exchange.
SEQUA.BR stock is listed on the Euronext Brussels exchange.
11 analysts have analysed SEQUA.BR and the average price target is 5.1 EUR. This implies a price increase of 242.28% is expected in the next year compared to the current price of 1.49. Check the SEQUANA MEDICAL NV stock analysts ratings, price target forecast and up-and down grades for more detailed information.
SEQUANA MEDICAL NV (SEQUA.BR) has a market capitalization of 78.11M EUR. This makes SEQUA.BR a Micro Cap stock.
SEQUANA MEDICAL NV (SEQUA.BR) currently has 62 employees.
SEQUANA MEDICAL NV (SEQUA.BR) has a support level at 1.45 and a resistance level at 1.65. Check the full technical report for a detailed analysis of SEQUA.BR support and resistance levels.
The Revenue of SEQUANA MEDICAL NV (SEQUA.BR) is expected to decline by -88.93% in the next year. Check the estimates tab for more information on the SEQUA.BR EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
SEQUA.BR does not pay a dividend.
SEQUANA MEDICAL NV (SEQUA.BR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.94).
ChartMill assigns a technical rating of 3 / 10 to SEQUA.BR. When comparing the yearly performance of all stocks, SEQUA.BR is one of the better performing stocks in the market, outperforming 88.68% of all stocks.
ChartMill assigns a fundamental rating of 1 / 10 to SEQUA.BR. SEQUA.BR has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months SEQUA.BR reported a non-GAAP Earnings per Share(EPS) of -0.94. The EPS increased by 24.72% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -251.92% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 84% to SEQUA.BR. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of 56.12% and a revenue growth -88.93% for SEQUA.BR